Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo
- 3 October 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (8), 856-867
- https://doi.org/10.1002/pros.21488
Abstract
BACKGROUND In this study, we investigated the effects of combining lenalidomide and docetaxel on in vitro and in vivo models of prostate cancer as a potential strategy for treatment of castrate resistant prostate cancer (CRPC). METHODS The effects of combining lenalidomide and docetaxel on proliferation, apoptosis, invasive potential, anchorage independent growth, and p53 activation in the PC3 and DU145 prostate cell lines were investigated. The effects of the lenalidomide and docetaxel combination on LNCaP prostate cancer cell growth and invasiveness in vitro was also studied. The combination of these two agents was finally tested on a xenograft model of PC3 tumor growth in nude mice. RESULTS Lenalidomide decreased the IC50 of docetaxel by up to 50% (P < 0.05) and also decreased invasion in PC3, LNCaP, and DU145 cells and anchorage independent growth in PC3 cells (P < 0.01). Apoptosis in lenalidomide/docetaxel-treated cells was increased by 2.2-fold over single agent docetaxel and a corresponding increase in p53, p38, and BAD activation was observed in Western blots (P < 0.001). When PC3 challenged mice were treated with lenalidomide and docetaxel, median survival increased from 48 to 59 days and the rate of tumor growth was significantly reduced (P < 0.05). CONCLUSIONS Lenalidomide may be a promising candidate for combination with docetaxel in the treatment of CRPC. Prostate 72:856–867, 2012.Keywords
This publication has 37 references indexed in Scilit:
- Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinomaBritish Journal of Cancer, 2009
- Oscillations of the p53-Akt Network: Implications on Cell Survival and DeathPLOS ONE, 2009
- Lenalidomide: a novel anticancer drug with multiple modalitiesExpert Opinion on Pharmacotherapy, 2008
- Inhibition of p38 MAPK Suppresses Inflammatory Cytokine Induction by Etoposide, 5-Fluorouracil, and Doxorubicin without Affecting Tumoricidal ActivityPLOS ONE, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- p53 and Bad: remote strangers become close friendsCell Research, 2007
- Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor CellsCancer Research, 2007
- Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathwayOncogene, 1999
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992